These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 23927666)

  • 1. An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma.
    Gedeon PC; Choi BD; Hodges TR; Mitchell DA; Bigner DD; Sampson JH
    Expert Rev Clin Pharmacol; 2013 Jul; 6(4):375-86. PubMed ID: 23927666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical Assessment of AMG 596, a Bispecific T-cell Engager (BiTE) Immunotherapy Targeting the Tumor-specific Antigen EGFRvIII.
    Sternjak A; Lee F; Thomas O; Balazs M; Wahl J; Lorenczewski G; Ullrich I; Muenz M; Rattel B; Bailis JM; Friedrich M
    Mol Cancer Ther; 2021 May; 20(5):925-933. PubMed ID: 33632870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting EGFRvIII for glioblastoma multiforme.
    Yang J; Yan J; Liu B
    Cancer Lett; 2017 Sep; 403():224-230. PubMed ID: 28649003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies.
    Zitron IM; Thakur A; Norkina O; Barger GR; Lum LG; Mittal S
    BMC Cancer; 2013 Feb; 13():83. PubMed ID: 23433400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting a glioblastoma cancer stem-cell population defined by EGF receptor variant III.
    Emlet DR; Gupta P; Holgado-Madruga M; Del Vecchio CA; Mitra SS; Han SY; Li G; Jensen KC; Vogel H; Xu LW; Skirboll SS; Wong AJ
    Cancer Res; 2014 Feb; 74(4):1238-49. PubMed ID: 24366881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.
    Sampson JH; Aldape KD; Archer GE; Coan A; Desjardins A; Friedman AH; Friedman HS; Gilbert MR; Herndon JE; McLendon RE; Mitchell DA; Reardon DA; Sawaya R; Schmittling R; Shi W; Vredenburgh JJ; Bigner DD; Heimberger AB
    Neuro Oncol; 2011 Mar; 13(3):324-33. PubMed ID: 21149254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.
    O'Rourke DM; Nasrallah MP; Desai A; Melenhorst JJ; Mansfield K; Morrissette JJD; Martinez-Lage M; Brem S; Maloney E; Shen A; Isaacs R; Mohan S; Plesa G; Lacey SF; Navenot JM; Zheng Z; Levine BL; Okada H; June CH; Brogdon JL; Maus MV
    Sci Transl Med; 2017 Jul; 9(399):. PubMed ID: 28724573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma.
    Miao H; Choi BD; Suryadevara CM; Sanchez-Perez L; Yang S; De Leon G; Sayour EJ; McLendon R; Herndon JE; Healy P; Archer GE; Bigner DD; Johnson LA; Sampson JH
    PLoS One; 2014; 9(4):e94281. PubMed ID: 24722266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma.
    Choi BD; Kuan CT; Cai M; Archer GE; Mitchell DA; Gedeon PC; Sanchez-Perez L; Pastan I; Bigner DD; Sampson JH
    Proc Natl Acad Sci U S A; 2013 Jan; 110(1):270-5. PubMed ID: 23248284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human macrophages engineered to secrete a bispecific T cell engager support antigen-dependent T cell responses to glioblastoma.
    Gardell JL; Matsumoto LR; Chinn H; DeGolier KR; Kreuser SA; Prieskorn B; Balcaitis S; Davis A; Ellenbogen RG; Crane CA
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33122397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel EGFRvIII T-Cell Bispecific Antibody for the Treatment of Glioblastoma.
    Iurlaro R; Waldhauer I; Planas-Rigol E; Bonfill-Teixidor E; Arias A; Nicolini V; Freimoser-Grundschober A; Cuartas I; Martínez-Moreno A; Martínez-Ricarte F; Cordero E; Cicuendez M; Casalino S; Guardia-Reyes X; Fahrni L; Pöschinger T; Steinhart V; Richard M; Briner S; Mueller J; Osl F; Sam J; Colombetti S; Bacac M; Klein C; Pineda E; Reyes-Figueroa L; Di Somma A; González J; Nuciforo P; Carles J; Vieito M; Tabernero J; Umaña P; Seoane J
    Mol Cancer Ther; 2022 Oct; 21(10):1499-1509. PubMed ID: 35915983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas.
    Del Vecchio CA; Li G; Wong AJ
    Expert Rev Vaccines; 2012 Feb; 11(2):133-44. PubMed ID: 22309662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma.
    Hadjipanayis CG; Machaidze R; Kaluzova M; Wang L; Schuette AJ; Chen H; Wu X; Mao H
    Cancer Res; 2010 Aug; 70(15):6303-12. PubMed ID: 20647323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models.
    Keir ST; Chandramohan V; Hemphill CD; Grandal MM; Melander MC; Pedersen MW; Horak ID; Kragh M; Desjardins A; Friedman HS; Bigner DD
    J Neurooncol; 2018 Jul; 138(3):489-498. PubMed ID: 29564747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of CRISPR/Cas9-Mediated PD-1-Disrupted Primary Human Third-Generation CAR-T Cells Targeting EGFRvIII on In Vitro Human Glioblastoma Cell Growth.
    Nakazawa T; Natsume A; Nishimura F; Morimoto T; Matsuda R; Nakamura M; Yamada S; Nakagawa I; Motoyama Y; Park YS; Tsujimura T; Wakabayashi T; Nakase H
    Cells; 2020 Apr; 9(4):. PubMed ID: 32316275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFRvIII as a promising target for antibody-based brain tumor therapy.
    Kuan CT; Wikstrand CJ; Bigner DD
    Brain Tumor Pathol; 2000; 17(2):71-8. PubMed ID: 11210174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma.
    Hamblett KJ; Kozlosky CJ; Siu S; Chang WS; Liu H; Foltz IN; Trueblood ES; Meininger D; Arora T; Twomey B; Vonderfecht SL; Chen Q; Hill JS; Fanslow WC
    Mol Cancer Ther; 2015 Jul; 14(7):1614-24. PubMed ID: 25931519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of immunomodulation in human glioblastoma.
    Avril T; Vauleon E; Tanguy-Royer S; Mosser J; Quillien V
    Immunotherapy; 2011 Apr; 3(4 Suppl):42-4. PubMed ID: 21524170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic Analysis of a Novel Human EGFRvIII:CD3 Bispecific Antibody in Plasma and Whole Blood Using a High-Resolution Targeted Mass Spectrometry Approach.
    Schaller TH; Foster MW; Thompson JW; Spasojevic I; Normantaite D; Moseley MA; Sanchez-Perez L; Sampson JH
    J Proteome Res; 2019 Aug; 18(8):3032-3041. PubMed ID: 31267741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFRvIII-CAR-T Cells with PD-1 Knockout Have Improved Anti-Glioma Activity.
    Zhu H; You Y; Shen Z; Shi L
    Pathol Oncol Res; 2020 Oct; 26(4):2135-2141. PubMed ID: 31989402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.